Fatal reactivation of hepatitis B virus infection in a patient with adult T-cell leukemia-lymphoma receiving the anti-CC chemokine receptor 4 antibody mogamulizumab

Hepatology Research

Volumn 45, Issue 13, 2015, Pages 1363-1367

  Ifuku, Hideki ^a   Kusumoto, Shigeru ^b   Tanaka, Yasuhito ^b   Totani, Haruhito ^b   Ishida, Takashi ^b   Okada, Masaya ^c   Murakami, Shuko ^b   Mizokami, Masashi ^d   Ueda, Ryuzo ^e   Iida, Shinsuke ^b  

^a Amagasaki Central Hospital   (Japan)

^b NAGOYA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCES   (Japan)

^c HYOGO COLLEGE OF MEDICINE   (Japan)

^d NATIONAL CENTER FOR GLOBAL HEALTH AND MEDICINE   (Japan)

^e AICHI MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Antiviral prophylaxis; CC chemokine receptor type 4; Hepatitis B virus; Mogamulizumab; Reactivation

Indexed keywords

ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CHEMOKINE RECEPTOR CCR4; CYCLOPHOSPHAMIDE; DOXORUBICIN; ENTECAVIR; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIGEN; HEPATITIS C ANTIBODY; HUMAN T CELL LEUKEMIA VIRUS ANTIBODY; LACTATE DEHYDROGENASE; MOGAMULIZUMAB; NEOMINOPHAGEN C; PIRARUBICIN; PREDNISOLONE; SOLUBLE INTERLEUKIN 2 RECEPTOR; VINCRISTINE;

ACUTE LIVER FAILURE; AGED; ARTICLE; ASCITES; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; CANCER GROWTH; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; ERYTHROCYTE TRANSFUSION; HEPATIC COMA; HEPATITIS B; HEPATOMEGALY; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; JAUNDICE; LYMPHADENOPATHY; MALE; MULTIPLE CYCLE TREATMENT; PLASMAPHERESIS; PLEURA EFFUSION; PRIORITY JOURNAL; SPLEEN DISEASE; T CELL LEUKEMIA; TREATMENT RESPONSE; VIRUS REACTIVATION;

EID: 84955187433     PISSN: 13866346     EISSN: 1872034X     Source Type: Journal    
DOI: 10.1111/hepr.12513     Document Type: Article

References (34)

1. Yeo W, Chan PK, Ho WM et al. Lamivudine for the prevention of hepatitis B virus reactivation in hepatitis B s-antigen seropositive cancer patients undergoing cytotoxic chemotherapy. J Clin Oncol 2004; 22: 927-34.
2. Umemura T, Tanaka E, Kiyosawa K, Kumada H. Mortality secondary to fulminant hepatic failure in patients with prior resolution of hepatitis B virus infection in Japan. Clin Infect Dis 2008; 47: e52-6.
3. Kusumoto S, Tanaka Y, Mizokami M, Ueda R. Reactivation of hepatitis B virus following systemic chemotherapy for malignant lymphoma. Int J Hematol 2009; 90: 13-23.
4. Evens AM, Jovanovic BD, Su YC et al. Rituximab-associated hepatitis B virus (HBV) reactivation in lymphoproliferative diseases: meta-analysis and examination of FDA safety reports. Ann Oncol 2011; 22: 1170-80.
5. Lok AS, Liang RH, Chiu EK, Wong KL, Chan TK, Todd D. Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy. Report of a prospective study. Gastroenterology 1991; 100: 182-8.
6. Yeo W, Chan PK, Hui P et al. Hepatitis B virus reactivation in breast cancer patients receiving cytotoxic chemotherapy: a prospective study. J Med Virol 2003; 70: 553-61.
7. Dervite I, Hober D, Morel P. Acute hepatitis B in a patient with antibodies to hepatitis B surface antigen who was receiving rituximab. N Engl J Med 2001; 344: 68-9.
8. Hui CK, Cheung WW, Zhang HY et al. Kinetics and risk of de novo hepatitis B infection in HBsAg-negative patients undergoing cytotoxic chemotherapy. Gastroenterology 2006; 131: 59-68.
9. Yeo W, Chan TC, Leung NW et al. Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab. J Clin Oncol 2009; 27: 605-11.
10. Drafting Committee for the Management of Hepatitis B Virus Infection and the Japan Society of Hepatology. JSH Guidelines for the Management of Hepatitis B Virus Infection. Hepatol Res 2014; 44(Suppl S1): 1-58.
11. European Association For The Study Of The Liver etal. EASL clinical practice guidelines: Management of chronic hepatitis B virus infection. J Hepatol 2012; 57: 167-85.
12. Di Bisceglie AM, Lok AS, Martin P, Terrault N, Perrillo RP, Hoofnagle JH. Recent FDA warnings on hepatitis B reactivation with immune-suppressing and anti-cancer drugs: Just the tip of the iceberg? Hepatology 2014; 61: 703-11.
13. Reddy KR, Beavers KL, Hammond SP, Lim JK, Falck-Ytter YT. American gastroenterological association institute guideline on the prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy. Gastroenterology 2015; 148: 215-9.
14. Ishida T, Utsunomiya A, Iida S et al. Clinical significance of CCR4 expression in adult T-cell leukemia/lymphoma: its close association with skin involvement and unfavorable outcome. Clin Cancer Res 2003; 9: 3625-34.
15. Ishii T, Ishida T, Utsunomiya A et al. Defucosylated humanized anti-CCR4 monoclonal antibody KW-0761 as a novel immunotherapeutic agent for adult T-cell leukemia/lymphoma. Clin Cancer Res 2010; 16: 1520-31.
16. Yamamoto K, Utsunomiya A, Tobinai K etal. Phase I study of KW-0761, a defucosylated humanized anti-CCR4 antibody, in relapsed patients with adult T-cell leukemia-lymphoma and peripheral T-cell lymphoma. J Clin Oncol 2010; 28: 1591-8.
17. Ishida T, Ueda R. Antibody therapy for Adult T-cell leukemia-lymphoma. Int J Hematol 2011; 94: 443-52.
18. Ishida T, Joh T, Uike N et al. Defucosylated anti-CCR4 monoclonal antibody (KW-0761) for relapsed adult T-cell leukemia-lymphoma: a multicenter phase II study. J Clin Oncol 2012; 30: 837-42.
19. Mochida S, Takikawa Y, Nakayama N et al. Diagnostic criteria of acute liver failure: A report by the Intractable Hepato-Biliary Diseases Study Group of Japan. Hepatol Res 2011; 41: 805-12.
20. Ishida T, Ueda R. Immunopathogenesis of lymphoma: focus on CCR4. Cancer Sci 2011; 102: 44-50.
21. Ogura M, Ishida T, Hatake K et al. Multicenter phase II study of mogamulizumab (KW-0761), a defucosylated anti-cc chemokine receptor 4 antibody, in patients with relapsed peripheral T-cell lymphoma and cutaneous T-cell lymphoma. J Clin Oncol 2014; 32: 1157-63.
22. Ishida T, Ito A, Sato F et al. Stevens-Johnson Syndrome associated with mogamulizumab treatment of adult T-cell leukemia / lymphoma. Cancer Sci 2013; 104: 647-50.
23. Yano H, Ishida T, Inagaki A et al. Regulatory T-cell function of adult T-cell leukemia/lymphoma cells. Int J Cancer 2007; 120: 2052-7.
24. Huang H, Li X, Zhu J et al. Entecavir vs lamivudine for prevention of hepatitis B virus reactivation among patients with untreated diffuse large B-cell lymphoma receiving R-CHOP chemotherapy: a randomized clinical trial. JAMA 2014; 312: 2521-30.
25. Chang TT, Gish RG, de Man R et al. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med 2006; 354: 1001-10.
26. Kim SJ, Hsu C, Song YQ et al. Hepatitis B virus reactivation in B-cell lymphoma patients treated with rituximab: analysis from the Asia Lymphoma Study Group. Eur J Cancer 2013; 49: 3486-96.
27. Tashiro T, Yamasaki T, Nagai H, Kikuchi H, Nasu M. Immunological studies on opportunistic infection and the development of adult T-cell leukemia. Intern Med 1992; 31: 1132-6.
28. Eizuru Y, Tamura K, Minamishima Y et al. Cytomegalovirus infections in adult T-cell leukemia patients. J Med Virol 1987; 23: 123-33.
29. Chisari FV. Rous-Whipple Award Lecture. Viruses, immunity, and cancer: lessons from hepatitis B. Am J Pathol 2000; 156: 1117-32.
30. Isogawa M, Tanaka Y. Immunobiology of hepatitis B virus infection. Hepatol Res 2015; 45: 179-89.
31. Omata M, Ehata T, Yokosuka O, Hosoda K, Ohto M. Mutations in the precore region of hepatitis B virus DNA in patients with fulminant and severe hepatitis. N Engl J Med 1991; 324: 1699-704.
32. Ozasa A, Tanaka Y, Orito E et al. Influence of genotypes and precore mutations on fulminant or chronic outcome of acute hepatitis B virus infection. Hepatology 2006; 44: 326-34.
33. Pei SN, Ma MC, Wang MC et al. Analysis of hepatitis B surface antibody titers in B cell lymphoma patients after rituximab therapy. Ann Hematol 2012; 91: 1007-12.
34. Westhoff TH, Jochimsen F, Schmittel A et al. Fatal hepatitis B virus reactivation by an escape mutant following rituximab therapy. Blood 2003; 102: 1930.